Clinical significance of coexisting histological diffuse type in stage II/III gastric cancer

Tanaka,Hiroaki; Yoshii,Mami; Imai,Takumi; Tamura,Tatsuro; Toyokawa,Takahiro; Muguruma,Kazuya; Hirakawa,Kosei; Ohira,Masaichi

doi:10.3892/mco.2021.2397

Clinical significance of coexisting histological diffuse type in stage II/III gastric cancer

Authors:
- Hiroaki Tanaka
- Mami Yoshii
- Takumi Imai
- Tatsuro Tamura
- Takahiro Toyokawa
- Kazuya Muguruma
- Kosei Hirakawa
- Masaichi Ohira
View Affiliations

Affiliations: Department of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka 545‑8585, Japan, Department of Medical Statistics, Osaka City University Graduate School of Medicine, Osaka 545‑8585, Japan
Published online on: September 17, 2021 https://doi.org/10.3892/mco.2021.2397
Article Number: 234
Copyright: © Tanaka et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Since 1965, the Laurén classification has been used most commonly for gastric adenocarcinoma, with two main types: intestinal type and diffuse type. Signet ring cell carcinoma (Sig) and non‑solid poorly differentiated adenocarcinoma (Por2) are the histological forms of diffuse type that are often found in advanced tumors, and they seem to be associated with a poor prognosis. S‑1‑based adjuvant chemotherapy for patients with stage II/III gastric cancer has generally been accepted in Japan, but histological type does not alter treatment strategy. The aim of the present study was to investigate the prognostic impact of the histopathological mixture of Sig and Por2 in patients with stage II/III gastric cancer treated with S‑1 adjuvant chemotherapy. The clinicopathological data of 968 patients with gastric carcinoma who underwent gastrectomy between 2007 and 2016 at Osaka City University Hospital were retrospectively analyzed. In the present study, tumors containing Sig or Por2 were classified as diffuse type, and those not containing them were classified as intestinal type. There were 307 cases of diffuse type and 661 cases of intestinal type. Diffuse type included 189 cases with Sig. A pathological diagnosis of Sig was an independent risk factor for peritoneal recurrence in patients with stage II/III gastric cancer. Patients with diffuse type had a worse overall survival rate than those with intestinal type at stage III gastric cancer. Among the patients who received S‑1 adjuvant chemotherapy, the prognosis of patients with stage III gastric cancer with Sig but not Por2 was significantly worse compared with that of patients with intestinal type. Therefore, the present study revealed that the coexistence of Sig in the primary tumor was associated with a poor prognosis in patients with stage III gastric cancer. The current findings suggested that, since mixed Sig gastric cancer had a high risk of peritoneal recurrence even if adjuvant chemotherapy was performed, the pathological diagnosis should be considered when determining the therapeutic strategy for adjuvant chemotherapy in patients with stage III gastric cancer.

View Figures

View References

1	Lauren P: The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 64:31–49. 1965.PubMed/NCBI View Article : Google Scholar
2	Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 14:101–112. 2011.PubMed/NCBI View Article : Google Scholar
3	Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, Washington KM, Carneiro F and Cree IA: WHO Classification of Tumours Editorial Board. The 2019 WHO classification of tumours of the digestive system. Histopathology. 76:182–188. 2020.PubMed/NCBI View Article : Google Scholar
4	Lee JH, Chang KK, Yoon C, Tang LH, Strong VE and Yoon SS: Lauren histologic type is the most important factor associated with pattern of recurrence following resection of gastric adenocarcinoma. Ann Surg. 267:105–113. 2018.PubMed/NCBI View Article : Google Scholar
5	Chen YC, Fang WL, Wang RF, Liu CA, Yang MH, Lo SS, Wu CW, Li AFY, Shyr YM and Huang KH: Clinicopathological variation of lauren classification in gastric cancer. Pathol Oncol Res. 22:197–202. 2016.PubMed/NCBI View Article : Google Scholar
6	Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T and Ohashi Y: Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 29:4387–4393. 2011.PubMed/NCBI View Article : Google Scholar
7	Yoshida K, Kodera Y, Kochi M, Ichikawa W, Kakeji Y, Sano T, Nagao N, Takahashi M, Takagane A, Watanabe T, et al: Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: Interim analysis of JACCRO GC-07, a randomized controlled trial. J Clin Oncol. 37:1296–1304. 2019.PubMed/NCBI View Article : Google Scholar
8	Petrelli F, Berenato R, Turati L, Mennitto A, Steccanella F, Caporale M, Dallera P, de Braud F, Pezzica E, Di Bartolomeo M, et al: Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: A systematic review and meta-analysis. J Gastrointest Oncol. 8:148–163. 2017.PubMed/NCBI View Article : Google Scholar
9	Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 513:202–209. 2014.PubMed/NCBI View Article : Google Scholar
10	Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, Liu J, Yue YG, Wang J, Yu K, et al: Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 21:449–456. 2015.PubMed/NCBI View Article : Google Scholar
11	Cislo M, Filip AA, Arnold Offerhaus GJ, Ciseł B, Rawicz-Pruszyński K, Skierucha M and Polkowski WP: Distinct molecular subtypes of gastric cancer: From Lauren to molecular pathology. Oncotarget. 9:19427–19442. 2018.PubMed/NCBI View Article : Google Scholar
12	Zheng HC, Li XH, Hara T, Masuda S, Yang XH, Guan YF and Takano Y: Mixed-type gastric carcinomas exhibit more aggressive features and indicate the histogenesis of carcinomas. Virchows Arch. 452:525–534. 2008.PubMed/NCBI View Article : Google Scholar
13	Fujimoto A, Ishikawa Y, Ishii T, Yamada A, Igarashi Y, Ohmoto Y and Kaise M: Differences between gastric signet-ring cell carcinoma and poorly differentiated adenocarcinoma: A comparison of histopathologic features determined by mucin core protein and trefoil factor family peptide immunohistochemistry. Pathol Int. 67:398–403. 2017.PubMed/NCBI View Article : Google Scholar
14	Pernot S, Voron T, Perkins G, Lagorce-Pages C, Berger A and Taieb J: Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge. World J Gastroenterol. 21:11428–11438. 2015.PubMed/NCBI View Article : Google Scholar
15	Li C, Kim S, Lai JF, Hyung WJ, Choi WH, Choi SH and Noh SH: Advanced gastric carcinoma with signet ring cell histology. Oncology. 72:64–68. 2007.PubMed/NCBI View Article : Google Scholar
16	Chon HJ, Hyung WJ, Kim C, Park S, Kim JH, Park CH, Ahn JB, Kim H, Chung HC, Rha SY, et al: Differential prognostic implications of gastric signet ring cell carcinoma: stage adjusted analysis from a single high-volume center in Asia. Ann Surg. 265:946–953. 2017.PubMed/NCBI View Article : Google Scholar
17	Lee SH, Jee SR, Kim JH and Seol SY: Intramucosal gastric cancer: The rate of lymph node metastasis in signet ring cell carcinoma is as low as that in well-differentiated adenocarcinoma. Eur J Gastroenterol Hepatol. 27:170–174. 2015.PubMed/NCBI View Article : Google Scholar
18	Machlowska J, Puculek M, Sitarz M, Terlecki P, Maciejewski R and Sitarz R: State of the art for gastric signet ring cell carcinoma: From classification, prognosis, and genomic characteristics to specified treatments. Cancer Manag Res. 11:2151–2161. 2019.PubMed/NCBI View Article : Google Scholar
19	Piessen G, Messager M, Leteurtre E, Jean-Pierre T and Mariette C: Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation. Ann Surg. 250:878–887. 2009.PubMed/NCBI View Article : Google Scholar
20	Yoshii M, Tanaka H, Ohira M, Muguruma K, Iwauchi T, Lee T, Sakurai K, Kubo N, Yashiro M, Sawada T and Hirakawa K: Expression of Forkhead box P3 in tumour cells causes immunoregulatory function of signet ring cell carcinoma of the stomach. Br J Cancer. 106:1668–1674. 2012.PubMed/NCBI View Article : Google Scholar
21	Jimenez Fonseca P, Carmona-Bayonas A, Hernandez R, Custodio A, Cano JM, Lacalle A, Echavarria I, Macias I, Mangas M, Visa L, et al: Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: Real-world data from the AGAMENON national cancer registry. Br J Cancer. 117:775–782. 2017.PubMed/NCBI View Article : Google Scholar
22	Yoon C, Cho SJ, Aksoy BA, Park DJ, Schultz N, Ryeom SW and Yoon SS: Chemotherapy resistance in diffuse-type gastric adenocarcinoma is mediated by RhoA activation in cancer stem-like cells. Clin Cancer Res. 22:971–983. 2016.PubMed/NCBI View Article : Google Scholar
23	Takahari D, Boku N, Mizusawa J, Takashima A, Yamada Y, Yoshino T, Yamazaki K, Koizumi W, Fukase K, Yamaguchi K, et al: Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan clinical oncology group 9912. Oncologist. 19:358–366. 2014.PubMed/NCBI View Article : Google Scholar
24	Koizumi W, Kim YH, Fujii M, Kim HK, Imamura H, Lee KH, Hara T, Chung HC, Satoh T, Cho JY, et al: Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: A randomized study (START). J Cancer Res Clin Oncol. 140:319–328. 2014.PubMed/NCBI View Article : Google Scholar